InfuSystem Hlds

InfuSystem Holdings, Inc. engages in the provision of healthcare services. It operates through the Integrated Therapy Services and Durable Medical Equipment segments. The Integrated Therapy Services segment focuses on providing electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics, and hospital outpatient oncology clinics. The Durable Medical Equipment segment is involved in the rental, sale or leasing of pole-mounted and ambulatory infusion pumps to oncology practices, hospitals, and other clinical settings. The company was founded in August 2005 and headquartered in Rochester Hills, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InfuSystem reports revenue growth but faces supply chain challenges

InfuSystem's Q4 2022 performance showed revenue growth but a decrease in adjusted EBITDA, with a focus on strategic partnerships and conservative guidance for 2023.
The company faces challenges with supply chain issues, reporting delays, and internal control deficiencies, but is actively addressing these issues.
Opportunities lie in expanding the supplier base, enhancing product offerings, and expecting gradual revenue growth in 2023, supported by key partnerships and growth initiatives.

InfuSystem reports record Q1 revenue, expands partnerships for growth

InfuSystem's Q1 2023 performance reflects strong revenue growth, successful partnerships, and strategic expansions, positioning the company for continued success in the healthcare services sector.
While facing challenges such as higher expenses and reimbursement complexities, InfuSystem's focus on innovation and financial stability underscores its resilience and growth potential.
By reaffirming annual guidance and emphasizing sustainable growth strategies, InfuSystem demonstrates a clear vision for driving profitability and market leadership in the coming quarters.

InfuSystem reports robust Q2 earnings, eyes growth in Wound Care

InfuSystem Holdings, Inc. delivered a strong performance in Q2 2023, driven by revenue growth and strategic business decisions. The company's financial results, progress in addressing internal control deficiencies, and raised guidance indicate a positive outlook for future growth. While challenges exist in scaling certain business segments, InfuSystem is well-positioned to capitalize on opportunities in Wound Care and the Sanara joint venture.

InfuSystem reports record Q3 revenue growth and strategic expansion plans

InfuSystem's Q3 2023 performance reflects robust revenue growth, improved profitability, and strategic initiatives for future expansion and operational efficiency.
While facing challenges such as margin pressures and market competition, the company's strengths in oncology and operational enhancements position it for long-term success.
Opportunities in revenue diversification, service expansion, and market presence offer InfuSystem avenues for sustained growth and profitability.
Overall, InfuSystem's strong financial results, strategic focus on growth drivers, and optimism for future performance paint a positive outlook for investors and stakeholders.

InfuSystem Hlds (INFU) reports record revenue in Q4 2023

InfuSystem Hlds (INFU) delivered a robust performance in Q4 2023, showcasing revenue growth and margin improvement. With a strategic focus on core business expansion and operational excellence, the company aims for steady growth in 2024 amidst industry challenges and regulatory changes.

InfuSystem reports strong Q1 revenue growth and strategic partnerships

InfuSystem's Q1 performance reflects revenue growth and profitability improvements driven by operational enhancements.
The company's strategic partnerships and focus on high-potential opportunities position it for sustained growth.
Challenges include market focus shifts and balancing expenses with revenue growth for long-term success.
Overall, InfuSystem's performance outlook remains positive, with confidence in achieving revenue and EBITDA targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InfuSystem Holdings, Inc. engages in the provision of healthcare services. It operates through the Patient Services and Device Solutions segments. The Patient Services segment involves the durable medical equipment, clinic-to-home health care, logistics and billing, and oncology business. The Device Solutions segment includes the sale or rent of new and pre-owned pole-mounted and ambulatory infusion pumps, treatment-related consumables, biomedical recertification, maintenance and repair services for oncology practices. The company was founded by Steven E. Watkins in August 2005 and headquartered in Rochester Hills, MI.

Revenues of $107 million - $110 million; Adjusted EBITDA of $29 million - $30 million; Operating Cash Flow of $21 million - $23 million; Revenues of $107 million - $110 million; Adjusted EBITDA of $29 million - $30 million; Operating Cash Flow of $21 million - $23 million;

InfuSystem Holdings, Inc. Issues Full Year 2021 Guidance  

Rochester Hills, Michigan, Dec. 14, 2020 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Rich DiIorio, Chief Executive Officer and Barry Steele, Chief Financial Officer, will present at the 13th Annual LD Micro Main Event at 3:00 p.m. ET on Tuesday, December 15, 2020, on a virtual platform.

InfuSystem to Present at 13th Annual LD Micro Main Event Tuesday, December 15, 2020

Conference Call to be held 9:00 a.m. Eastern Time Conference Call to be held 9:00 a.m. Eastern Time

InfuSystem to Announce Full Year 2021 Guidance on Tuesday, December 15, 2020

ROCHESTER HILLS, Michigan, Nov. 16, 2020 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that Rich DiIorio, Chief Executive Officer and Barry Steele, Chief Financial Officer, will present at the following investor conferences:

InfuSystem to Present at Craig-Hallum Capital Group and Sidoti & Company Investment Conferences

InfuSystem Holdings Inc. (INFU) CEO Rich Dilorio on Q3 2020 Results - Earnings Call Transcript

Revenue: $25.1 million, a 17% increase vs. Prior Year Net Income: $2.9 million, an increase of 159%, and Adjusted EBITDA: $7.5 million, a 46% increase

InfuSystem Holdings, Inc. Reports Financial Results for the Third Quarter 2020

Investor Conference Call to be held 9:00 a.m. Eastern Time Investor Conference Call to be held 9:00 a.m. Eastern Time

InfuSystem to Report Third Quarter 2020 Financial Results on Thursday, November 12, 2020

InfuSystem Is Just Getting Started

Investor Presentation to be held 3:15 p.m. Eastern Time Investor Presentation to be held 3:15 p.m. Eastern Time

InfuSystem to Present at Sidoti’s Fall 2020 Investor Conference September 23, 2020

ROCHESTER HILLS, Michigan, Sept.  09, 2020  (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that Richard DiIorio, Chief Executive Officer and Barry Steele, Chief Financial Officer, will present at Lake Street’s 4th Annual Best Ideas Growth (BIG4) Conference, being held on Thursday, September 17, 2020, on a virtual platform.

InfuSystem to Present at Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020

InfuSystems (NYSE: INFU) shares are trading higher on Monday after Craig-Hallum initiated coverage on the stock with a Buy rating and a price target of $28 per share.

Why InfuSystems' Stock Is Trading Higher Today

Rochester Hills, Michigan, Aug.  25, 2020  (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Richard DiIorio, Chief Executive Officer and Barry Steele, Chief Financial Officer, will present at the LD 500 Virtual Conference on Tuesday, September 1, 2020 at 9:40 a.m. ET.

InfuSystem Holdings, Inc. Presents at the LD 500 Virtual Conference on September 1, 2020

InfuSystem Holdings Inc. (INFU) CEO Rich Dilorio on Q2 2020 Results - Earnings Call Transcript

InfuSystem to Report Second Quarter 2020 Financial Results on Thursday, August 13, 2020

Rochester Hills, Michigan, June  18, 2020  (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today its addition to the FTSE Russell 2000® Index, following the Russell US Index’s Annual Reconstitution, effective after the market closes on June 26, 2020.

InfuSystem to Join FTSE Russell 2000® Index

Investor Presentation to be held 1:00 p.m. Eastern Time Investor Presentation to be held 1:00 p.m. Eastern Time

InfuSystem to Present at Lytham Partners Virtual Investor Conference

InfuSystem Holdings Inc. (INFU) CEO Rich DiIorio on Q1 2020 Results - Earnings Call Transcript

The company is still on pace to join the Russell2000, which should provide a huge tailwind to a thinly-traded name.

InfuSystem: Negative Pressure On Shares From Covid-19 Will Subside

InfuSystem Holdings, Inc. (INFU) CEO Rich DiIorio on Q4 2019 Results - Earnings Call Transcript

ROCHESTER HILLS, Michigan, March  12, 2020  (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment (“DME”) manufacturers and health care providers, today announced that Barry G. Steele has joined the Company as Chief Financial Officer, effective immediately after the Company files its annual report on Form 10-K for the year ended December 31, 2019.

InfuSystem Names Barry G. Steele as New Chief Financial Officer

ROCHESTER HILLS, MICHIGAN, Feb.  11, 2020  (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment (“DME”) manufacturers and health care providers, announced today that it has entered into an agreement whereby it will add Negative Pressure Wound Therapy (“NPWT”) to its Integrated Therapy Service (“ITS”) platform.  As part of the new relationship, InfuSystem’s turnkey solutions will include providing the durable medical equipment, overseeing logistics, biomedical services, and managing third-party billing.

InfuSystem Enters Negative Pressure Wound Therapy Market

﻿ROCHESTER HILLS, MICHIGAN, Feb.  07, 2020  (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national healthcare service provider facilitating outpatient care for durable medical equipment (“DME”) manufacturers and health care providers, announced today that Gregory Schulte, Executive Vice President and Chief Financial Officer of InfuSystem, and the Company have agreed to a mutual separation.  Mr. Schulte’s departure is not the result of any disagreement with the Company regarding its operations or accounting policies or practices. The Company has appointed Wesley W. Winnekins as Interim Chief Financial Officer, effective immediately.

InfuSystem Retains Heidrick & Struggles for Nationwide CFO Search; Appoints Interim CFO

InfuSystem's Operating Leverage Reaches Inflection Point

InfuSystem Holdings Inc.'s (INFU) CEO Rich DiIorio on Q3 2019 Results - Earnings Call Transcript

MADISON HEIGHTS, MICHIGAN, Oct.  02, 2019  (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American LLC: INFU) (“InfuSystem” or the “Company”), a leading national provider of infusion pumps and related services for the healthcare industry in the United States and Canada, today announced that Carrie Lachance has been promoted to Chief Operating Officer, effective October 1, 2019.

News for InfuSystem Hlds Stock (INFU)